INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, has announced its participation in the Baird 2024 Global Healthcare Conference in New York, NY. The company's management will present on Tuesday, September 10, 2024, from 8:30-9:00 AM Eastern Time in Session III, Empire Ballroom B, Mezzanine Level.
INmune Bio focuses on developing treatments that harness a patient's innate immune system to fight disease. This conference presentation provides an opportunity for the company to showcase its progress and engage with investors in the healthcare sector. The Baird Global Healthcare Conference is a significant event that brings together industry leaders and investors to discuss advancements in healthcare.
INmune Bio Inc. (NASDAQ: INMB), un'azienda in fase clinica specializzata in infiammazione e immunologia, ha annunciato la sua partecipazione al Baird 2024 Global Healthcare Conference a New York, NY. La direzione dell'azienda presenterà martedì 10 settembre 2024, dalle 8:30 alle 9:00 ora orientale nella Sessione III, Empire Ballroom B, livello mezzanino.
INmune Bio si concentra sullo sviluppo di trattamenti che sfruttano il sistema immunitario innato del paziente per combattere le malattie. Questa presentazione al convegno offre un'opportunità all'azienda per mostrare i suoi progressi e interagire con gli investitori nel settore sanitario. La Baird Global Healthcare Conference è un evento significativo che riunisce leader del settore e investitori per discutere i progressi nel campo della sanità.
INmune Bio Inc. (NASDAQ: INMB), una empresa en etapa clínica especializada en inflamación e inmunología, ha anunciado su participación en la Baird 2024 Global Healthcare Conference en Nueva York, NY. La dirección de la empresa presentará el martes 10 de septiembre de 2024, de 8:30 a 9:00 AM hora del Este en la Sesión III, Empire Ballroom B, Nivel Mezzanine.
INmune Bio se centra en el desarrollo de tratamientos que aprovechan el sistema inmunológico innato de los pacientes para combatir enfermedades. Esta presentación en la conferencia brinda a la empresa la oportunidad de mostrar su progreso y conectar con inversores en el sector de la salud. La Baird Global Healthcare Conference es un evento importante que reúne a líderes de la industria e inversores para discutir los avances en el cuidado de la salud.
INmune Bio Inc. (NASDAQ: INMB), 임상 단계의 염증 및 면역학 회사가 뉴욕 NY에서 열리는 Baird 2024 Global Healthcare Conference에 참여한다고 발표했습니다. 회사의 경영진은 2024년 9월 10일 화요일 오전 8시 30분부터 9시까지 동부 표준시에 세션 III, Empire Ballroom B, Mezzanine Level에서 발표할 예정입니다.
INmune Bio는 환자의 선천 면역 체계를 활용하여 질병과 싸우는 치료법을 개발하는 데 집중하고 있습니다. 이번 컨퍼런스 발표는 회사가 자신의 진행 상황을 보여주고 의료 분야의 투자자들과 소통할 수 있는 기회를 제공합니다. Baird Global Healthcare Conference는 산업 리더와 투자자들이 모여 의료 분야의 발전에 대해 논의하는 중요한 행사입니다.
INmune Bio Inc. (NASDAQ: INMB), une entreprise en phase clinique spécialisée dans l'inflammation et l'immunologie, a annoncé sa participation à la Baird 2024 Global Healthcare Conference à New York, NY. La direction de l'entreprise présentera le mardi 10 septembre 2024, de 8h30 à 9h00 heure de l'Est lors de la session III, Empire Ballroom B, niveau mezzanine.
INmune Bio se concentre sur le développement de traitements qui exploitent le système immunitaire inné des patients pour lutter contre les maladies. Cette présentation lors de la conférence offre à l'entreprise l'opportunité de mettre en avant ses avancées et d'interagir avec les investisseurs du secteur de la santé. La Baird Global Healthcare Conference est un événement important qui réunit des leaders de l'industrie et des investisseurs pour discuter des avancées dans le domaine de la santé.
INmune Bio Inc. (NASDAQ: INMB), ein Unternehmen in der klinischen Phase, das sich auf Entzündungen und Immunologie spezialisiert hat, hat seine Teilnahme an der Baird 2024 Global Healthcare Conference in New York, NY, angekündigt. Das Management des Unternehmens wird am Dienstag, den 10. September 2024, von 8:30 bis 9:00 Uhr Eastern Time in Sitzung III, Empire Ballroom B, Mezzanine-Ebene präsentieren.
INmune Bio konzentriert sich auf die Entwicklung von Behandlungen, die das angeborene Immunsystem des Patienten nutzen, um Krankheiten zu bekämpfen. Diese Konferenzpräsentation bietet dem Unternehmen die Möglichkeit, seine Fortschritte zu präsentieren und mit Investoren im Gesundheitssektor in Kontakt zu treten. Die Baird Global Healthcare Conference ist eine bedeutende Veranstaltung, die Fachleute der Branche und Investoren zusammenbringt, um über Fortschritte im Gesundheitswesen zu diskutieren.
- None.
- None.
Boca Raton, Florida, Sept. 03, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that management will participate in the following investor conferences in September and October, 2024.
Baird 2024 Global Healthcare Conference
New York, NY; September 10-11, 2024
Presentation Time: Tuesday, September 10 at 8:30-9:00 AM Eastern Time
Location: Session III, Empire Ballroom B, Mezzanine Level
About INmune Bio Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. XPRO, the first of several DN-TNF products, is in clinical trials to determine if it can treat patients with Mild Alzheimer’s disease. Additional therapeutic indications including d treatment-resistant depression and oncology will be pursued when resources allow. The Natural Killer Cell Priming Platform includes INKmune™, a therapy developed to prime a patient’s NK cells to treat patients with cancer. INKmune uses a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies. The INKmune trial is enrolling patients into a US Phase I/II trial in men with metastatic castrate resistant prostate cancer. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO (858) 964-3720
info@inmunebio.com
Investor Contact:
Mike Moyer
Managing Director – LifeSci Advisors
mmoyer@lifesciadvisors.com
FAQ
When is INmune Bio (INMB) presenting at the Baird 2024 Global Healthcare Conference?
Where is the Baird 2024 Global Healthcare Conference being held?
What is the focus of INmune Bio's (INMB) research and development?
In which room will INmune Bio (INMB) be presenting at the Baird conference?
What is the stock symbol for INmune Bio on NASDAQ?
